Newer Disease-Modifying Agents for Rheumatoid Arthritis
For a patient with ongoing erosive progression despite methotrexate 20-25 mg weekly and prednisolone 10 mg daily, you should add a biologic DMARD (bDMARD) or JAK inhibitor (targeted synthetic DMARD) to the methotrexate regimen immediately.
Current Treatment Status and Next Steps
Your patient has failed adequate methotrexate therapy (at optimal dosing) and represents a clear indication for treatment escalation. The 2019 EULAR guidelines specifically address this scenario: when poor prognostic factors are present (erosive disease qualifies), addition of a bDMARD or JAK inhibitor should be considered 1.
Available Newer Agents
JAK Inhibitors (Targeted Synthetic DMARDs)
The most significant newer class includes:
- Tofacitinib (first approved)
- Baricitinib
- Upadacitinib
- Filgotinib
These oral agents represent a major advancement since the 2013-2014 guidelines 1. The 2019 EULAR recommendations state that with poor prognostic factors (which includes erosive progression), any bDMARD or JAK inhibitor should be added to the csDMARD 1.
Biologic DMARDs
Newer biologics since earlier guidelines include:
- Sarilumab (IL-6 receptor inhibitor, similar mechanism to tocilizumab)
- Biosimilars of established biologics (adalimumab, etanercept, infliximab, rituximab)
The 2021 ACR guidelines also recognize these JAK inhibitors as equivalent options to biologics for patients failing methotrexate 2, 3.
Critical Safety Considerations
Important caveat: The 2025 EULAR update emphasizes careful consideration of cardiovascular and malignancy risks with JAK inhibitors 4. For patients with:
- Age ≥65 years
- Cardiovascular risk factors
- History of malignancy
- Risk of thromboembolic events
Biologics should be prioritized over JAK inhibitors 4.
Sequencing Algorithm
First-line escalation: Add any TNF inhibitor, abatacept, tocilizumab, sarilumab, or (with appropriate risk assessment) a JAK inhibitor to methotrexate 1
If first bDMARD/JAKi fails: Switch to any other bDMARD from another or the same class, or to a JAK inhibitor (considering risks) 1, 4
Tofacitinib positioning: The 2013 EULAR guidelines originally recommended tofacitinib after biological treatment failure 5, but the 2019 update elevated JAK inhibitors to equal footing with biologics as first-line options after methotrexate failure 1
Addressing the Prednisolone Issue
Your patient is on 10 mg prednisolone daily, which exceeds recommended duration and dose. The guidelines strongly recommend:
- Glucocorticoids should be tapered as rapidly as clinically feasible 5
- Longer-term (≥3 months) glucocorticoids are strongly recommended against 2, 3
- The 2025 update reiterates short-term use only 4
Once the bDMARD/JAKi is added and disease control improves, aggressive prednisolone tapering should be prioritized to minimize long-term glucocorticoid toxicity.
Practical Considerations
Cost and access: Biosimilars offer equivalent efficacy to originator biologics at reduced cost 1, 2. This may influence sequencing decisions based on your healthcare system.
Monitoring: Assess treatment response within 3-6 months; if inadequate, switch to another bDMARD or JAK inhibitor rather than continuing ineffective therapy 1.